Nucor earnings beat by $0.08, revenue fell short of estimates
Investing.com - Cantor Fitzgerald has reiterated an Overweight rating on Neurocrine Biosciences (NASDAQ:NBIX) with a price target of $170.00 ahead of the company’s second-quarter earnings report. According to InvestingPro data, analyst targets currently range from $115 to $192, with a strong consensus recommendation of 1.48 (Buy).
The biopharmaceutical company is scheduled to release its 2Q25 financial results on July 30, with Cantor noting that NBIX shares typically experience volatility around earnings announcements, averaging moves of approximately 6% in either direction over recent years. InvestingPro analysis shows the company maintains a GREAT financial health score of 3.42, with impressive revenue growth of 21.7% over the last twelve months.
The research firm expressed high confidence in Crenessity performance while maintaining low to medium confidence in Ingrezza results, acknowledging that quarterly earnings for NBIX have historically been difficult to predict with precision.
Cantor highlighted that NBIX shares have moved more than 5% following each of the last four earnings reports, with the first quarter of 2025 seeing an 8% increase after a significant 18% decline following fourth-quarter 2024 results, which had included disappointing 2025 guidance.
The firm also observed that NBIX shares have traded higher after 75% of earnings reports over the past three years, suggesting favorable historical odds for positive stock movement following earnings announcements.
In other recent news, Neurocrine Biosciences has been the focus of several key developments. UBS raised its price target for the company to $174 from $152, maintaining a Buy rating due to positive indicators from the Crenessity drug launch. Similarly, Truist Securities initiated coverage with a Buy rating, expressing optimism about Crenessity’s potential to drive future growth. Goldman Sachs also initiated coverage with a Buy rating, highlighting Neurocrine’s attractive growth outlook, particularly with the ongoing Crenessity launch and the commercial prospects of Ingrezza.
Additionally, Neurocrine Biosciences reported positive one-year data for its CRENESSITY (crinecerfont) treatment in adults with classic congenital adrenal hyperplasia (CAH), showing lasting reductions in glucocorticoid doses and improved clinical outcomes. This data complements previous findings in pediatric studies. A separate analysis revealed challenges in managing CAH, with significant variability in glucocorticoid treatment regimens reported. These findings were presented at the Endocrine Society’s Annual Meeting in San Francisco.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.